Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging. (June 2015)

• Record Type: Journal Article
• Authors: Boeri, Mattia; Sestini, Stefano; Fortunato, Orazio; Verri, Carla; Suatoni, Paola; Pastorino, Ugo; Sozzi, Gabriella
• Is Part Of: Expert review of molecular diagnostics. Volume 15:Number 6(2015)
• Page Start: 801
• Page End: 813
• Publication Date: 2015-06
• Subjects: Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1586/14737159.2015.1041377
• Languages: English
• ISSNs: 1473-7159

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Lung cancer is the leading cause of cancer deaths in the world. Advances in early detection crucial to enable timely curative surgery have been made in recent years. Cost–benefit profiles of lung cancer screening in smokers by low-dose computed tomography are still under evaluation. In particular, the high false-positive rates of low-dose computed tomography, together with the issue of overdiagnosis and the overall costs of screening, prompted a focus on the development of noninvasive complementary biomarkers to implement lung cancer screening. MicroRNA are a new class of blood-based biomarkers useful for early lung cancer detection and prognosis definition. Here, we discuss the seminal publications that reported circulating microRNA signatures with the greatest potential to impact clinical activity and patient care.</p> </abstract>